# PADA-1 (NCT03079011)

> PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03079011
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: UNICANCER
- Conditions: Metastatic Breast Cancer
- Interventions: Palbociclib 125mg; Aromatase Inhibitors; Fulvestrant Injectable Product
- Enrollment: 1017
- Primary outcome: Incidence of treatment-emergent Adverse Events
- Primary outcome: Progression-free survival (Step 2)

## Commentary we found

- YouTube: 58
- Podcasts: 36
- X threads: 28

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=pada-1-nct03079011

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03079011", "email": "<work email>"}; the inbox owner confirms by the emailed link.